{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:53:40Z","timestamp":1790873620299,"version":"4.1.0"},"reference-count":82,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain Circ"],"published-print":{"date-parts":[[2020]]},"DOI":"10.4103\/bc.bc_57_19","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T10:08:14Z","timestamp":1593166094000},"page":"96","source":"Crossref","is-referenced-by-count":35,"title":["Pregabalin-associated movement disorders: A literature review"],"prefix":"10.4103","volume":"6","author":[{"given":"JamirPitton","family":"Rissardo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AnaLet\u00edcia Fornari","family":"Caprara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/2394-8108.287739-1","first-page":"8","article-title":"Profile of the anticonvulsant activity of CI-1008 (pregabalin) in animal models","author":"Taylor","year":"1997","journal-title":"Epilepsia"},{"key":"key-10.4103\/2394-8108.287739-2","first-page":"143","article-title":"Pregabalin-associated myoclonus","author":"Asconape","year":"1999","journal-title":"Epilepsia"},{"key":"key-10.4103\/2394-8108.287739-3","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1212\/01.WNL.0000068024.20285.65","article-title":"Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures","author":"French","year":"2003","journal-title":"Neurology"},{"key":"key-10.4103\/2394-8108.287739-4","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrd1756","article-title":"Pregabalin?","author":"Dworkin","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"key-10.4103\/2394-8108.287739-5","unstructured":"ClinCalc. The Top 300 of 2020. Available from: https:\/\/clincalccom\/DrugStats\/Top300Drugsaspx. [Last accessed on 2020 May 23]."},{"key":"key-10.4103\/2394-8108.287739-6","unstructured":"Cross AL, Viswanath O, Sherman Al. Pregabalin. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470341\/. [Last updated 2020 Mar 26]."},{"key":"key-10.4103\/2394-8108.287739-7","doi-asserted-by":"crossref","unstructured":"Stahl SM, Porreca F, Taylor CP, Cheung R, Thorpe AJ, Clair A. The diverse therapeutic actions of pregabalin: Is a single mechanism responsible for several pharmacological activities? Trends Pharmacol Sci 2013;34:332-9.","DOI":"10.1016\/j.tips.2013.04.001"},{"key":"key-10.4103\/2394-8108.287739-8","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nrn3311","article-title":"Calcium channel auxiliary \u03b1 2 \u03b4 and \u03b2 subunits: Trafficking and one step beyond","author":"Dolphin","year":"2012","journal-title":"Nat Rev Neurosci"},{"key":"key-10.4103\/2394-8108.287739-9","doi-asserted-by":"crossref","unstructured":"Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev 2009;(3):CD007076. Published 2009 Jul 8. doi:10.1002\/14651858.CD007076.pub2.","DOI":"10.1002\/14651858.CD007076.pub2"},{"key":"key-10.4103\/2394-8108.287739-10","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1212\/01.WNL.0000150932.48688.BE","article-title":"Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy","author":"Beydoun","year":"2005","journal-title":"Neurology"},{"key":"key-10.4103\/2394-8108.287739-11","doi-asserted-by":"crossref","first-page":"5","DOI":"10.14712\/23362936.2020.1","article-title":"Buspirone-associated movement disorder: A literature review","author":"Rissardo","year":"2020","journal-title":"Prague Med Rep"},{"key":"key-10.4103\/2394-8108.287739-12","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/WNF.0000000000000387","article-title":"Carbamazepine-, oxcarbazepine-, eslicarbazepine-associated movement disorder: A literature review","author":"Rissardo","year":"2020","journal-title":"Clin Neuropharmacol"},{"key":"key-10.4103\/2394-8108.287739-13","doi-asserted-by":"crossref","first-page":"236","DOI":"10.47102\/annals-acadmed.sg.202023","article-title":"The link between amitriptyline and movement disorders: Clinical profile and outcome","author":"Rissardo","year":"2020","journal-title":"Ann Acad Med Singapore"},{"key":"key-10.4103\/2394-8108.287739-14","unstructured":"Jankovic J, Tolosa E. Parkinson's Disease and Movement Disorders. Philadelphia: Lippincott Williams & Wilkins; 2007."},{"key":"key-10.4103\/2394-8108.287739-15","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"key-10.4103\/2394-8108.287739-16","first-page":"417","article-title":"No longer lost in translation: Evidence that Google translate works for comparative bag-of-words text applications","author":"De","year":"2018","journal-title":"Polit Anal"},{"key":"key-10.4103\/2394-8108.287739-17","doi-asserted-by":"crossref","first-page":"148","DOI":"10.4274\/Tnd.63497","article-title":"A dyskinesia case induced by pramipexole, pregabalin and gabapentin after cardiopulmonary resuscitation","author":"Aksoy","year":"2013","journal-title":"Turk J Neurol"},{"key":"key-10.4103\/2394-8108.287739-18","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.0013-9580.2004.31203.x","article-title":"Pregabalin add-on treatment: A randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures","author":"Arroyo","year":"2004","journal-title":"Epilepsia"},{"key":"key-10.4103\/2394-8108.287739-19","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.eplepsyres.2010.05.008","article-title":"A comparison of pregabalin, lamotrigine, and placebo as adjunctive therapy in patients with refractory partial-onset seizures","author":"Baulac","year":"2010","journal-title":"Epilepsy Res"},{"key":"key-10.4103\/2394-8108.287739-20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ebcr.2012.10.003","article-title":"Myoclonic status epilepticus in six patients without epilepsy","author":"Baysal","year":"2013","journal-title":"Epilepsy Behav Case Rep"},{"key":"key-10.4103\/2394-8108.287739-21","unstructured":"Ari BC, Domac FM, Kenangil GO. A Case of Pregabalin induced Parkinsonism [abstract]. Mov Disord 2019;34 (Suppl 2). Available from: https:\/\/www.mdsabstracts.org\/abstract\/a-case-of-pregabalin-induced-parkinsonism\/. [Last accessed 2020 Jun 11]."},{"key":"key-10.4103\/2394-8108.287739-22","first-page":"48","article-title":"Pregabalin-associated myoclonic encephalopathy without evidence of drug accumulation in a patient with acute renal failure","author":"Courtois","year":"2014","journal-title":"Indian J Nephrol","ISSN":"https:\/\/id.crossref.org\/issn\/0971-4065","issn-type":"print"},{"key":"key-10.4103\/2394-8108.287739-23","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1345\/aph.1R699","article-title":"Pregabalin-induced akathisia","author":"Dag","year":"2013","journal-title":"Ann Pharmacother"},{"key":"key-10.4103\/2394-8108.287739-24","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jocn.2018.09.019","article-title":"Gabapentin or pregabalin induced myoclonus: A case series and literature review","author":"Desai","year":"2019","journal-title":"J Clin Neurosci"},{"key":"key-10.4103\/2394-8108.287739-25","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1111\/j.1528-1167.2005.00341.x","article-title":"Pregabalin add-on treatment in patients with partial seizures: A novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study","author":"Elger","year":"2005","journal-title":"Epilepsia"},{"key":"key-10.4103\/2394-8108.287739-26","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/JCP.0000000000000609","article-title":"Pregabalin-associated stuttering in a patient with complex regional pain syndrome: A case report","author":"Giray","year":"2016","journal-title":"J Clin Psychopharmacol"},{"key":"key-10.4103\/2394-8108.287739-27","first-page":"20","article-title":"Myoclonus in an elderly patient: Case report","author":"Gosavi","year":"2011","journal-title":"Reactions"},{"key":"key-10.4103\/2394-8108.287739-28","doi-asserted-by":"crossref","unstructured":"Hamlyn A, Foo K, Bhatia A, Bobrin B. Manifestations of pregabalin withdrawal. J Psychiatry 2017;20:418. [doi: 10.4172\/2378-5756.1000418].","DOI":"10.4172\/2378-5756.1000418"},{"key":"key-10.4103\/2394-8108.287739-29","doi-asserted-by":"crossref","unstructured":"Shneker BF, McAuley JW. Pregabalin: A new neuromodulator with broad therapeutic indications. Ann Pharmacother 2005;39:2029-37.","DOI":"10.1345\/aph.1G078"},{"key":"key-10.4103\/2394-8108.287739-30","first-page":"6","article-title":"Asterixis in elderly patients: 2 case reports","author":"Han","year":"2008","journal-title":"Reactions"},{"key":"key-10.4103\/2394-8108.287739-31","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1002\/mds.22286","article-title":"Pregabalin- and gabapentin-associated myoclonus in a patient with chronic renal failure","author":"Healy","year":"2009","journal-title":"Mov Disord"},{"key":"key-10.4103\/2394-8108.287739-32","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1097\/01.phm.0000176355.97155.f5","article-title":"Pregabalin associated asterixis","author":"Heckmann","year":"2005","journal-title":"Am J Phys Med Rehabil"},{"key":"key-10.4103\/2394-8108.287739-33","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.yebeh.2008.04.006","article-title":"Pregabalin-induced cortical negative myoclonus in a patient with neuropathic pain","author":"Hellwig","year":"2008","journal-title":"Epilepsy Behav"},{"key":"key-10.4103\/2394-8108.287739-34","first-page":"63","article-title":"Abdominal pain challenge to manage in an elderly patient","author":"Hern\u00e1ndez","year":"2019","journal-title":"Dolor"},{"key":"key-10.4103\/2394-8108.287739-35","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.yebeh.2008.04.021","article-title":"Efficacy and tolerability of pregabalin in patients with difficult-to-treat epilepsy and intellectual disability","author":"Huber","year":"2008","journal-title":"Epilepsy Behav"},{"key":"key-10.4103\/2394-8108.287739-36","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1046\/j.1528-1157.2001.44000.x","article-title":"Myoclonus in epilepsy patients with anticonvulsive add-on therapy with pregabalin","author":"Huppertz","year":"2001","journal-title":"Epilepsia"},{"key":"key-10.4103\/2394-8108.287739-37","doi-asserted-by":"crossref","unstructured":"Kim JB, Jung JM, Park MH, Lee EJ, Kwon DY. Negative myoclonus induced by gabapentin and pregabalin: A case series and systematic literature review. J Neurol Sci 2017;382:36-9.","DOI":"10.1016\/j.jns.2017.09.019"},{"key":"key-10.4103\/2394-8108.287739-38","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.yebeh.2007.06.012","article-title":"Pregabalin-induced generalized myoclonic status epilepticus in patients with chronic pain","author":"Knake","year":"2007","journal-title":"Epilepsy Behav"},{"key":"key-10.4103\/2394-8108.287739-39","first-page":"1461","article-title":"Regardless of impaired renal function, negative myoclonus can be induced by gabapetin and pregabalin","author":"Kwon","year":"2019","journal-title":"Mov Disord"},{"key":"key-10.4103\/2394-8108.287739-40","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/jhm.701","article-title":"Pregabalin-induced trismus in a leukemia patient","author":"Kwong","year":"2011","journal-title":"J Hosp Med"},{"key":"key-10.4103\/2394-8108.287739-41","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1528-1167.2008.01954.x","article-title":"Pregabalin add-on therapy using a flexible, optimized dose schedule in refractory partial epilepsies: A double-blind, randomized, placebo-controlled, multicenter trial","author":"Lee","year":"2009","journal-title":"Epilepsia"},{"key":"key-10.4103\/2394-8108.287739-42","first-page":"138","article-title":"Two cases of pregabalin neurotoxicity in chronic kidney disease patients","author":"Lee","year":"2011","journal-title":"NDT Plus"},{"key":"key-10.4103\/2394-8108.287739-43","first-page":"395","article-title":"Pregabalin-induced Parkinsonism: A case report","author":"Masmoudi","year":"233;","journal-title":"Th"},{"key":"key-10.4103\/2394-8108.287739-44","first-page":"E349","article-title":"Muscle rigidity associated with pregabalin","author":"Matsuki","year":"2012","journal-title":"Pain Physician"},{"key":"key-10.4103\/2394-8108.287739-45","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.yebeh.2008.05.003","article-title":"Adjunctive pregabalin therapy in mentally retarded, developmentally delayed patients with epilepsy","author":"Modur","year":"2008","journal-title":"Epilepsy Behav"},{"key":"key-10.4103\/2394-8108.287739-46","unstructured":"Murphy N, Mosher L, editors. Severe myoclonus from pregabalin (lyrica) due to chronic renal insufficiency. In: Clinical Toxicology. New York, NY 10017 USA: Informa Healthcare 52 Vanderbilt Ave; 2008."},{"key":"key-10.4103\/2394-8108.287739-47","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.parkreldis.2015.04.026","article-title":"Speech myoclonus due to probable pregabalin adverse drug-reaction","author":"Olszewska","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"key":"key-10.4103\/2394-8108.287739-48","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1080\/24750573.2017.1422959","article-title":"Nasal pregabalin overdose and myclonus: A new way of misuse","author":"Ozturk","year":"2019","journal-title":"Psychiatry Clin Psychopharmacol"},{"key":"key-10.4103\/2394-8108.287739-49","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/mds.27876","article-title":"Parkinsonism associated with gabapentinoid drugs: A pharmacoepidemiologic study","author":"Pacheco-Paez","year":"2020","journal-title":"Mov Disord"},{"key":"key-10.4103\/2394-8108.287739-50","doi-asserted-by":"crossref","first-page":"240","DOI":"10.12701\/yujm.2018.35.2.240","article-title":"Negative myoclonus associated with pregabalin","author":"Park","year":"2018","journal-title":"Yeungnam Univ J Med"},{"key":"key-10.4103\/2394-8108.287739-51","doi-asserted-by":"crossref","first-page":"313","DOI":"10.4306\/pi.2009.6.4.313","article-title":"Resolution of pregabalin and mirtazapine associated restless legs syndrome by bupropion in a patient with major depressive disorder","author":"Park","year":"2009","journal-title":"Psychiatry Investig"},{"key":"key-10.4103\/2394-8108.287739-52","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/WNF.0b013e3181a9eb1b","article-title":"Pregabalin-induced Parkinsonism: A case report","author":"Perez","year":"2009","journal-title":"Clin Neuropharmacol"},{"key":"key-10.4103\/2394-8108.287739-53","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/jppr.1363","article-title":"Pregabalin-induced Parkinsonism 72 hours after iodinated contrast administration","author":"Prado-Mel","year":"2018","journal-title":"J Pharm Pract Res"},{"key":"key-10.4103\/2394-8108.287739-54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpainsymman.2018.10.496","article-title":"The possible preventive role of pregabalin in postmastectomy pain syndrome: A double-blinded randomized controlled trial","author":"Reyad","year":"2019","journal-title":"J Pain Symptom Manage"},{"key":"key-10.4103\/2394-8108.287739-55","first-page":"2927","article-title":"Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy","author":"Saif","year":"2010","journal-title":"Anticancer Res"},{"key":"key-10.4103\/2394-8108.287739-56","doi-asserted-by":"crossref","first-page":"bcr2012007559","DOI":"10.1136\/bcr-2012-007559","article-title":"Disturbance of consciousness and involuntary movements caused by pregabalin","author":"Shimizu","year":"2012","journal-title":"BMJ Case Rep"},{"key":"key-10.4103\/2394-8108.287739-57","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/24734306.2018.1458465","article-title":"Pregabalin and paradoxical reaction of seizures in a large overdose","author":"Slocum","year":"2018","journal-title":"Toxicol Commun"},{"key":"key-10.4103\/2394-8108.287739-58","first-page":"30","article-title":"Myoclonus in an elderly patient: Case report","author":"Sluyts","year":"2007","journal-title":"Reactions"},{"key":"key-10.4103\/2394-8108.287739-59","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1053\/j.ajkd.2009.04.014","article-title":"Treatment of pregabalin toxicity by hemodialysis in a patient with kidney failure","author":"Yoo","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"key-10.4103\/2394-8108.287739-60","doi-asserted-by":"crossref","unstructured":"Zaccara G, Gangemi P, Perucca P, Specchio L. The adverse event profile of pregabalin: A systematic review and meta-analysis of randomized controlled trials. Epilepsia 2011;52:826-36.","DOI":"10.1111\/j.1528-1167.2010.02966.x"},{"key":"key-10.4103\/2394-8108.287739-61","unstructured":"Friedman LM, Furberg C, DeMets DL, Reboussin DM, Granger CB. Fundamentals of Clinical Trials. 5th ed. New York: Springer; 2010."},{"key":"key-10.4103\/2394-8108.287739-62","doi-asserted-by":"crossref","unstructured":"Pulman J, Hemming K, Marson AG. Pregabalin add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2014;(3):CD005612. Published 2014 Mar 12. doi:10.1002\/14651858.CD005612.pub3","DOI":"10.1002\/14651858.CD005612.pub3"},{"key":"key-10.4103\/2394-8108.287739-63","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/brain\/101.3.447","article-title":"Electroencephalographic studies myoclonus","author":"Shibasaki","year":"1978","journal-title":"Brain"},{"key":"key-10.4103\/2394-8108.287739-64","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S1474-4422(04)00880-4","article-title":"Myoclonus: Current concepts and recent advances","author":"Caviness","year":"2004","journal-title":"Lancet Neurol"},{"key":"key-10.4103\/2394-8108.287739-65","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11940-016-0404-7","article-title":"Myoclonus: Pathophysiology and treatment options","author":"Levy","year":"2016","journal-title":"Curr Treat Options Neurol"},{"key":"key-10.4103\/2394-8108.287739-66","first-page":"137","article-title":"Asterixis: One type of negative myoclonus","author":"Young","year":"1986","journal-title":"Adv Neurol"},{"key":"key-10.4103\/2394-8108.287739-67","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/brain\/awf080","article-title":"The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service","author":"Hughes","year":"2002","journal-title":"Brain"},{"key":"key-10.4103\/2394-8108.287739-68","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/14737175.2019.1592676","article-title":"An update on myoclonus management","author":"Stahl","year":"2019","journal-title":"Expert Rev Neurother"},{"key":"key-10.4103\/2394-8108.287739-69","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3390\/brainsci7080103","article-title":"Myoclonic disorders","author":"Eberhardt","year":"2017","journal-title":"Brain Sci"},{"key":"key-10.4103\/2394-8108.287739-70","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4306\/pi.2009.6.2.55","article-title":"Does pregabalin have neuropsychotropic effects.A short perspective?","author":"Marks","year":"2009","journal-title":"Psychiatry Investig"},{"key":"key-10.4103\/2394-8108.287739-71","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.2147\/NDT.S3257","article-title":"New treatment options in the management of fibromyalgia: Role of pregabalin","author":"Zareba","year":"2008","journal-title":"Neuropsychiatr Dis Treat"},{"key":"key-10.4103\/2394-8108.287739-72","first-page":"261","article-title":"Idiopathic Parkinson's disease: Epidemiology, diagnosis and management","author":"Ben-Shlomo","year":"1995","journal-title":"Br J Gen Pract"},{"key":"key-10.4103\/2394-8108.287739-73","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/mds.870130313","article-title":"Cinnarizine-induced Parkinsonism: Ten years later","author":"Mart\u00ed-Mass\u00f3","year":"1998","journal-title":"Mov Disord"},{"key":"key-10.4103\/2394-8108.287739-74","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.neures.2007.10.007","article-title":"Effects of substance Pon neuronal firing of pallidal neurons in parkinsonian rats","author":"Cui","year":"2008","journal-title":"Neurosci Res"},{"key":"key-10.4103\/2394-8108.287739-75","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1111\/j.1460-9568.2007.05803.x","article-title":"SubstancePexcites globus pallidus neurons in vivo","author":"Cui","year":"2007","journal-title":"Eur J Neurosci"},{"key":"key-10.4103\/2394-8108.287739-76","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/0006-8993(90)90733-R","article-title":"Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease","author":"Halliday","year":"1990","journal-title":"Brain Res"},{"key":"key-10.4103\/2394-8108.287739-77","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.clinph.2018.04.048","article-title":"T47.Is stuttering a focal dystonia?","author":"Vreeswijk","year":"2018","journal-title":"Clin Neurophysiol"},{"key":"key-10.4103\/2394-8108.287739-78","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0301-0082(96)00042-1","article-title":"The basal ganglia: Focused selection and inhibition of competing motor programs","author":"Mink","year":"1996","journal-title":"Prog Neurobiol"},{"key":"key-10.4103\/2394-8108.287739-79","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3389\/fnhum.2019.00336","article-title":"No evidence for dystonia-like sensory overflow of tongue representations in adults who stutter","author":"Vreeswijk","year":"2019","journal-title":"Front Hum Neurosci"},{"key":"key-10.4103\/2394-8108.287739-80","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1152\/jn.00317.2003","article-title":"Dynamic equilibrium of neurotransmitter transporters: Not just for reuptake anymore","author":"Richerson","year":"2003","journal-title":"J Neurophysiol"},{"key":"key-10.4103\/2394-8108.287739-81","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1600-0404.2007.00796.x","article-title":"Pregabalin in restless legs syndrome with and without neuropathic pain","author":"Sommer","year":"2007","journal-title":"Acta Neurol Scand"},{"key":"key-10.4103\/2394-8108.287739-82","doi-asserted-by":"crossref","first-page":"273","DOI":"10.4088\/JCP.09r05268yel","article-title":"Antipsychotic medication and oxidative cell stress: A systematic review","author":"Lepping","year":"2011","journal-title":"J Clin Psychiatry"}],"container-title":["Brain Circulation"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:47:31Z","timestamp":1786733251000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/bc.bc_57_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":82,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"alternative-id":["287739"],"URL":"https:\/\/doi.org\/10.4103\/bc.bc_57_19","relation":{},"ISSN":["2394-8108"],"issn-type":[{"value":"2394-8108","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}